A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

Clinical trial NCT03884829 · TERMINATED

Trial details

NCT number: NCT03884829
Sponsor: Cyclacel Pharmaceuticals, Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

AML, Adult Myelodysplastic Syndromes ALL, Adult CML, Refractory CLL, Refractory

Start date: 2019-03-25
Primary completion: 2021-11-29
Enrollment: 7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.